http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012111695-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-416 |
| filingDate | 2010-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012111695-A |
| titleOfInvention | Fluoro-substituted 3,5-dicyano-4- (1H-indazole-5-yl) -2, 6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof |
| abstract | 1. The compound of formula (I) in which R is hydrogen, fluoro, methyl or ethyl, R is methyl, difluoromethyl or trifluoromethyl, R is hydrogen or fluoro, R is hydrogen, methyl or ethyl, and R is hydrogen or methyl, or a pharmaceutically acceptable salt, hydrate and / or solvate. 2. The compound of formula (I) according to claim 1, wherein R is hydrogen, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof. 3. The compound of formula (I) according to claim 1, wherein R is hydrogen or fluorine, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof. The compound of formula (I) according to claim 1, in which R is hydrogen or fluorine, R is methyl or difluoromethyl, R is hydrogen or fluorine, R is hydrogen or methyl, and R is hydrogen, or a pharmaceutically acceptable salt, hydrate and / or solvate thereof. The compound of formula (I) according to claim 1, wherein the compound is selected from the group consisting of race-2-methyl-4- (3-methyl-1H-indazol-5-yl) -6- (trifluoromethyl) -1,4-dihydropyridine- 3,5-dicarbonitrile; (4R) -2-methyl-4- (3-methyl-1H-indazol-5-yl) -6- (trifluoromethyl) -1,4-dihydropyridin-3,5-dicarbonitrile; (4S ) -2-methyl-4- (3-methyl-1H-indazol-5-yl) -6- (trifluoromethyl) -1,4-dihydropyridin-3,5-dicarbonitrile; rac-2- (difluoromethyl) -4- (6-fluoro-3-methyl-1H-indazol-5-yl) -6-methyl-1,4-dihydropyridin-3,5-dicarbonitrile; (4R) -2- (difluoromethyl) -4- (6-fluoro -3-methyl-1H-indazol-5-yl) -6-methyl-1,4-dihydropyridin-3,5-dicarbonitrile; (4S) -2- (difluoromethyl) -4- (6-fluoro-3-methyl -1H-ind zol-5-yl) -6-methyl-1,4-dihydropyridin-3,5-dicarbonitrile; 2,6-bis (difluoromethyl) -4- (3-methyl-1H-indazol-5-yl) -1, 4-dihydropyridin-3,5-dicarbonitrile; 2,6-bis (difluoromethyl) -4- (6-fluoro-3-methyl-1H-indazol-5-yl) -1,4-dihydropyridin-3,5-dicarbonitrile ; irats-4- (6-fluoro-1H-indazol-5-yl) -2-methyl-6- (trifluoromethyl) -1,4-dihydropyridin-3,5-dicarbonitrile; or a pharmaceutically acceptable salt thereof, hyd |
| priorityDate | 2009-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 70.